Ras-Like Without CAAX 2 (RIT2) antibody

Antigen: Ras-Like Without CAAX 2 (RIT2)

Synonyms: RIN, RIBA, ROC2, Rin, Roc2, Rit1, MGC109463, RIT2

Clonality: Polyclonal

Host: Rabbit

Reactivity: Caenorhabditis elegans (C. elegans), Human, Mouse (Murine), Zebrafish (Danio rerio)

Application: ELISA, Immunoprecipitation (IP), Western Blotting (WB)

Catalog no.: ABIN117958

Additional Information

Alternative name: ROC2

UniProt: Q0J9X2

Immunogen: Prepared from whole rabbit serum produced by repeated immunizations with a syntheticpeptide corresponding to amino acids 102-113 of Human ROC2 (C-terminal) coupled to KLH. AA Sequence: Human ROC2 (113 aa 12. 6 kDa)1 madvedgeet calashsgss gsksggdkmf slkkwnavam wswdvecdtc aicrvqvmda61 clrcqaenkq edcvvvwgec nhsfhnccms lwvkqnnrcp lcqqdwvvqr igk

Cross-Reactivity: Caenorhabditis elegans (C. elegans), Human, Mouse (Murine)

Description: ROC1 also known as RING-box protein 2, Rbx2, RING finger protein 7, Regulator of cullins 2,CKII betabinding protein 1, and CKBBP1, is a probable component of the SCF(SKP1-CUL1-F-box protein) and the CBC(VHL) (CUL2-elonging BC-VHL) E3 ubiquitin ligasecomplexes, which mediate the ubiquitination and subsequent proteasomal degradation oftarget proteins involved in cell cycle progression, signal transduction and transcription. ROC2 appears to recruit the E2 ubiquitination enzyme through the RING-type zinc finger ina manner similar to CDC34, and brings it into close proximity to the substrate. ROC2 mayplay a role in protecting cells from apoptosis induced by redox agents. ROC2 has acytoplasmic and nuclear localization and is expressed in heart, liver, skeletal muscle andpancreas tissues, and at very low levels in brain, placenta and lung. 1,10-phenanthrolineinduces ROC2 expression. The RING-type zinc finger domain is essential for ubiquitinligase activity. Phosphorylation by CK2 is required for efficient degradation of NFKBIA andCDKN1B.

Characteristics: Synonyms: GL2-2, Homeobox-leucine zipper protein ROC2, GLABRA 2-like homeobox protein 2, HD-ZIPprotein ROC2, Homeodomain transcription factor ROC2, Protein RICE OUTERMOSTCELL-SPECIFIC 2

Application Details

Application Notes: This antibody reacts with human ROC2 by Western blot (1: 500-1: 1,000) andImmunoprecipitation. The antibody immunoprecipitates in vitro translated protein andprotein from overexpressing cell lysates (using HeLa and NIH-3T3, and others). Coimmunoprecipitation of related proteins does occur. A 12.6 kDa band corresponding tohuman ROC2 is detected. Most cell lines expressing ROC2 can be used as a positive control. Other applications not tested. Optimal dilutions are dependent on conditions and should be determined by the user.

Concentration: 85 mg/ml (by Refractometry)

Purification: Serum

Storage: Store vial at -20°C prior to opening. Aliquot contents and freeze at -20°C or below forextended storage. Centrifuge product if not completely clear after standing at roomtemperature. This product is stable for one month at 2-8°C as an undiluted liquid. Diluteonly prior to immediate use. Avoid cycles of freezing and thawing. Shelf life: one year from despatch.

Restrictions: For Research Use only

Images

Conjugation pathways for ubiquitin and ubiquitin-like modifiers (UBLs). Most modifiers mature by proteolytic processing from inactive precursors (a, amino acid). Arrowheads point to the cleavage sites. Ubiquitin is expressed either as polyubiquitin or as a fusion with ribosomal proteins. Conjugation requires activating (E1) and conjugating (E2) enzymes that form thiolesters (S) with the modifiers. Modification of cullins by RUB involves SCF(SKP1/cullin-1/F-box protein) /CBC(cullin-2/elongin B/elonginC) -like E3 enzymes that are also involved in ubiquitination. In contrast to ubiquitin, the UBLs do not seem to form multi-UBL chains. UCRP(ISG15) resembles two ubiquitin moieties linked headto- tail. Whether HUB1 functions as a modifier is currently unclear. APG12 and URM1 are distinct from the other modifiers because they are unrelated in sequence to ubiquitin. Data contributed by S.Jentsch, see references below.

Publications

Kamura, Koepp, Conrad et al.: "Rbx1, a component of the VHL tumor suppressor complex and SCF ubiquitin ligase." in: Science (New York, N.Y.), Vol. 284, Issue 5414, pp. 657-61, 1999 (PubMed).

Furukawa, Zhang, McCarville et al.: "The CUL1 C-terminal sequence and ROC1 are required for efficient nuclear accumulation, NEDD8 modification, and ubiquitin ligase activity of CUL1." in: Molecular and cellular biology, Vol. 20, Issue 21, pp. 8185-97, 2000 (PubMed).

Jung, Park, Pae et al.: "[Short-term therapy with pegylated interferon plus ribavirin for the chronic hepatitis C genotype 2 patients]" in: The Korean journal of hepatology, Vol. 13, Issue 3, pp. 341-8, 2007 (PubMed).

Kim, Choi, Park et al.: "Endometrial stromal sarcoma of the small bowel: a case report and review of literature." in: Annals of diagnostic pathology, Vol. 12, Issue 2, pp. 128-33, 2008 (PubMed).